AMSTERDAM, Sept. 26, 2011 /PRNewswire/ -- InterMune, Inc. (NASDAQ:ITMN) today reported that new data(1) was presented at the European Respiratory Society (ERS) Annual Congress supporting the longer-term safety and tolerability of Esbriet® (pirfenidone) in patients with idiopathic...